Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024

NCT06683937 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Immunocompromised Patients
SARS-CoV-2 Disease

Interventions

OTHER: Collection of data from the patient's medical file

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]